A transformative in vivo model with diverse advantages in human health discovery
The nematode worm, C. elegans, offers diverse advantages for research discovery in human health applications. C. elegans share a high degree of gene conservation with humans, with several comparative signalling pathways and processes.
They are small (<1mm) whole organisms, with a short lifecycle, sharing a proportion of complexity to mammals, and are amenable to transgenic studies. When compared to rodents, they offer cost efficient, fast, more ethical primary stage testing for your project, in larger populations.
Established whole organism model for research testing, screening and disease with consistent physiology, compared to variable in vitro cells
No regulatory constraints, 3R compliant and more ethical to use than more sentient mammals
Get results in weeks rather than months. Much faster than comparable rodent studies, or tests in multiple in vitro cell types, or using organoids
Obtain multi-end point data at a fraction of the cost of comparable rodent studies.
Our patented novel WormGazerTM technology generates rich, customisable, multi-faceted healthspan data in a natural environment
Our world-class team of multidisciplinary C. elegans experts, holding 80+ years joint experience, ensure the best study design and analysis for your project
For complex diseases and conditions involving multiple organs and biological processes, C. elegans offer distinct advantages to in vitro cell studies. Their use as a model also proffers complementary data, to validate and enrich in vitro findings.
C.elegans provide an excellent natural model for ageing and longevity studies, as opposed to accelerated ageing model alternatives. They start to age within 1 week of their 2-3 week lifespan. In contrast, primary cell lines can be limited as a model for ageing, due to the huge variability in the biological age of individual cells. Mammalian models age relatively slowly and requirensubstantial upkeep, so are less time and cost-efficient.
C. elegans short lifecycle also makes it particularly suited to Developmental and Reproductive Toxicity (DART) studies and longevity studies.
Crucially, our CRO expertise and C. elegans in vivo testing enable you to prescreen and narrow your candidate pipeline, and consequently, reduce rodent testing. This is all without the regulatory requirements for tests in mammals.
We combine the amenability of C. elegans with our unrivalled CRO expertise and proprietary WormGazerTM technology to provide you with rich, high quality in vivo data with a multi-faceted healthspan approach. Our technology offers fast results, whilst maintaining worms in a natural environment rather than on microchips, (like some competitors), to encourage native behaviour.
We therefore generate optimal and reliable data outcomes. We have extensive experience across sectors, including academia, and work with clients in Biotechnology, Nutraceuticals & Ingredients, Pharmaceutical and Cosmeceuticals industries.
Our patented biophotonics platform analyses and captures multiple end-point data from living worms, providing rich integrated measures on the effect of your compound or product. In contrast to manual assays, that are well-established in academic research to measure health, ageing, toxicity (death) and disease in C. elegans, our WormGazerTM Technology allows us to collect continuous and rich data well beyond traditional manual assays.
SERVICES
Sign up to our newsletter today, to get access to the latest company and industry news
